Building R&D Capabilities In China – Spotlight On Pfizer
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Multinational pharmaceutical companies have moved beyond debating whether to open R&D operations in China to debating whether to open "brick and mortar" operations or "virtual" operations via outsourcing, according to speakers at the China 2008 Pharmaceutical R&D Summit in Shanghai
You may also be interested in...
Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference
SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks
Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference
SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks
GSK Jumps Into Growing China R&D Space
GlaxoSmithKline has joined a growing list of big pharma companies expanding in China, launching a research and development center based in Shanghai, the company announced May 24